1. Corticosteroid treatment for uveitic macular oedema shows promise
A clinical trial to evaluate the effectiveness of three different intravitreal treatments for persistent or recurrent uveitic macular oedema found that dexamethasone was significantly better at treating the condition.
Researchers looked at 225 eyes in 194 patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular oedema in one or both eyes. Patients at 33 clinical centres across the US, UK, Australia and India each received one of three therapies: dexamethasone implant, methotrexate or ranibizumab.
At 12 weeks, dexamethasone was found to be significantly better at treating persistent or recurrent macular oedema, giving a 35% reduction in central subfield thickness compared with 22% for ranibizumab and 11% for methotrexate.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The UK Eye Care Data Hub, the most up-to-date and comprehensive model of the UK’s eye care workforce and eye diseases in one place, has been expanded to almost double the number of eye conditions and update aspects of the sector workforce data.
The College of Optometrists has teamed up with road safety charity IAM RoadSmart to encourage drivers of all ages to see clearly when it comes to vision and driving standards.
Glaucoma is the second leading cause of irreversible sight loss in the UK and affects over one million people, which is predicted to rise by 100,000 cases to 1.145 million people by 2030*.